Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Ann Rheum Dis. 2016 Jan 19;75(11):1998–2006. doi: 10.1136/annrheumdis-2015-208410

Figure 1.

Figure 1

DNA methylation level of the IFI44L promoter and its sensitivity and specificity in the discovery cohort (Chinese cohort 1). (A) shows the position of the interrogated sequence within the IFI44L promoter region in the human genome (HG19). (B) and (C) show that the two CpG sites within the IFI44L promoter are significantly hypomethylated in the blood of patients with systemic lupus erythematosus (SLE) compared with healthy controls (HCs) and patients with rheumatoid arthritis (RA) (p < 0.001 for all comparisons). (D–G) show the receiver operating characteristic (ROC) curves of the DNA methylation levels at Site1 and Site2 in patients with SLE compared with HCs (D and E) and patients with RA (F and G), respectively.